tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Антинеопластични средства - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
co-irbesan 150 mg/12,5 mg film - coated tablets
Нобел Фарма ООД - ирбесартан и hydrochlrthiazide - 150 mg/12,5 mg film - coated tablets
co-irbesan 300 mg/12,5 mg film - coated tablets
Нобел Фарма ООД - 300 mg/12,5 mg film - coated tablets
co-irbesan 300 mg/25 mg film - coated tablets
Нобел Фарма ООД - 300 mg/25 mg film - coated tablets
irbesan 300 mg film - coated tablets
Нобел Фарма ООД - Ирбесартан - 300 mg film - coated tablets
irbesan 150 mg film - coated tablets
Нобел Фарма ООД - Ирбесартан - 150 mg film - coated tablets